NO942515L - Fremgangsmåte for fremstilling av preparater for vedvarende frigiving - Google Patents

Fremgangsmåte for fremstilling av preparater for vedvarende frigiving

Info

Publication number
NO942515L
NO942515L NO942515A NO942515A NO942515L NO 942515 L NO942515 L NO 942515L NO 942515 A NO942515 A NO 942515A NO 942515 A NO942515 A NO 942515A NO 942515 L NO942515 L NO 942515L
Authority
NO
Norway
Prior art keywords
water
soluble polypeptide
sustained release
preparation
release preparations
Prior art date
Application number
NO942515A
Other languages
English (en)
Norwegian (no)
Other versions
NO942515D0 (no
Inventor
Yasutaka Igari
Kazumichi Yamamoto
Kayoko Okamoto
Yutaka Yamagata
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO942515D0 publication Critical patent/NO942515D0/no
Publication of NO942515L publication Critical patent/NO942515L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO942515A 1993-07-05 1994-07-04 Fremgangsmåte for fremstilling av preparater for vedvarende frigiving NO942515L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16579393 1993-07-05
JP8176594 1994-04-20

Publications (2)

Publication Number Publication Date
NO942515D0 NO942515D0 (no) 1994-07-04
NO942515L true NO942515L (no) 1995-01-06

Family

ID=26422772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942515A NO942515L (no) 1993-07-05 1994-07-04 Fremgangsmåte for fremstilling av preparater for vedvarende frigiving

Country Status (11)

Country Link
US (1) US5534269A (de)
EP (1) EP0633020B1 (de)
KR (1) KR950002748A (de)
CN (1) CN1106653A (de)
AT (1) ATE184480T1 (de)
AU (1) AU674077B2 (de)
CA (1) CA2127317C (de)
DE (1) DE69420632T2 (de)
FI (1) FI943205L (de)
NO (1) NO942515L (de)
NZ (1) NZ260909A (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
AU6242096A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6190702B1 (en) 1996-03-28 2001-02-20 Takeda Chemical Industries, Ltd. Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
ATE235231T1 (de) * 1998-01-21 2003-04-15 Takeda Chemical Industries Ltd Verfahren zur gerfriertrocknung von präparaten mit verzörgerter wirkstoffabgabe
WO1999048519A1 (en) 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
FR2778847A1 (fr) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implant injectable en sous gingival resorbable, constitue de microspheres a liberation prolongee et chargees en principes actifs et en suspension dans un gel vecteur
US6165509A (en) * 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
CA2383144A1 (en) 1999-09-17 2001-03-29 Takeda Chemical Industries, Ltd. Process for producing protein powder
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
KR20030027077A (ko) * 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP4460892B2 (ja) 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
EP1466596B8 (de) * 2001-12-26 2017-01-11 Takeda Pharmaceutical Company Limited Mikrosphäre und verfahren zu deren herstellung
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
ES2427092T3 (es) 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CN1774281B (zh) * 2003-04-15 2010-10-13 奥珀百思控股公司 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
CN1852687B (zh) * 2003-07-15 2014-01-22 赢创有限公司 控释组合物的制备方法
JP5165240B2 (ja) * 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
DE102004046102B4 (de) * 2004-09-23 2009-09-03 Mars Inc. Indikatorgranulat
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101199623B (zh) * 2006-12-16 2011-04-27 石茂光 治疗高血压药物缓控释制剂的制备方法
EP2167039B1 (de) * 2007-05-18 2016-09-28 Durect Corporation Verbesserte depot-formulierungen
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104288123B (zh) * 2014-10-27 2016-09-14 浙江理工大学 一种负载干扰素微胶囊的制备方法
CN110404115B (zh) * 2019-07-23 2022-03-18 广东省医疗器械研究所 一种具有表面坑洞的碳酸盐/可降解高分子微球及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles

Also Published As

Publication number Publication date
DE69420632D1 (de) 1999-10-21
CA2127317A1 (en) 1995-01-06
CN1106653A (zh) 1995-08-16
FI943205A7 (fi) 1995-01-06
NO942515D0 (no) 1994-07-04
EP0633020A1 (de) 1995-01-11
ATE184480T1 (de) 1999-10-15
AU674077B2 (en) 1996-12-05
FI943205L (fi) 1995-01-06
CA2127317C (en) 2008-10-07
EP0633020B1 (de) 1999-09-15
FI943205A0 (fi) 1994-07-05
US5534269A (en) 1996-07-09
AU6614594A (en) 1995-01-12
NZ260909A (en) 1995-04-27
DE69420632T2 (de) 2000-03-02
KR950002748A (ko) 1995-02-16

Similar Documents

Publication Publication Date Title
NO942515L (no) Fremgangsmåte for fremstilling av preparater for vedvarende frigiving
ES2114183T3 (es) Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
IL131651A0 (en) A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
DK0642334T3 (da) Farmaceutiske og andre doseringsformer
BR9709845A (pt) Preparação aquosa de insulina formulação farmacêutica parenteral e processo para aumentar a estabilidade química de uma preparação de insulina
AU3160100A (en) Covalently bridged insulin dimers
DK0909562T3 (da) Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
GB1524431A (en) Production of long acting insulin preparations
ES2053460T3 (es) Un procedimiento para recuperar antibioticos glicopeptidicos.
TW364008B (en) Process for binding lignocellulosic material
EP0326111A3 (de) Peptid-Derivate, immunogenisch gemacht bei Verabreichung zusammen mit Alaun als Zusatzmittel
ES477212A1 (es) Un procedimiento para la preparacion de una enterotoxina.
EP0800828A4 (de) Transmucosale zubereitung
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
CA2090701A1 (en) Solubilization of proteins in active forms
BR9611683A (pt) Processo para a preparação de compostos
FI903660A0 (fi) Foerfarande foer hydrering av nitroaromatiska halogenderivat i naervaro av jodider.
DE3872213D1 (de) 5-substituierte ornithin-derivate.
ES2104686T3 (es) Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.
NO975339L (no) Jodderingsprosess
FI884418A7 (fi) Sydäntä suojaava aine ja terapeuttinen aine iskeemisiin sairauksiin sisältäen N-sisältäviä, heterosyklisiä yhdisteitä, ja menetelmä näiden yhdisteiden valmistamiseksi.
KR890008166A (ko) 융합 단백질의 선택적 분해 방법
AU4034095A (en) Cyclohexapeptides and their mixtures, a process for preparing them, and their use
IT1298268B1 (it) Procedimento per la preparazione dell'acido (s)-2-bromo-3-fenil- propionico
ES8303288A1 (es) Procedimiento de obtencion de la n-(trans-4-hidroxi-ciclo- hexil-)-(2-amino-3,5-dibromo)bencilamina y sus sales farma- ceuticamente aceptables.